Anna Planavila Porta
Anna Planavila began her scientific career in 2001, which culminated in the defense of her doctoral thesis in 2005 at the Faculty of Pharmacy of the University of Barcelona, with the obtaining of the Outstanding Cum Laude and the Extraordinary Doctorate Prize 2006 In 2005-2007 he completed his first postdoctoral stay at Maastricht Cardiovascular Research Institute (CARIM) (The Nehterlands) thanks to a competitive MEC / Fulbright postdoctoral fellowship (Ministry of Education and Science of Spain). After this, Sara Borrell, Carlos III Health Institute, MCINN, obtained a competitive postdoctoral contract for research at the Faculty of Biology. University of Barcelona (2008-2011).
Between 2012-2016 she worked as a researcher and associate professor at the Faculty of Biology (University of Barcelona). And in 2016 he obtained a Ramón y Cajal contract, which allowed him to establish his independent research laboratory.
He currently directs the research line called "Molecular Cardiology", within the research group "Molecular biology and gene regulation of adipose tissue and its pathologies". The group's activity has been sustained, in addition to the financial support associated with the Ramón y Cajal program (€ 40,000), successfully obtaining various competitive grants that it directed. Between 2015-2017, he obtained a competitive grant from MINECO to the Biomedicine program of the National Plan MINECO, specifically to the JIN program (SAF2014-55702-JIN, € 170,000). In addition, it obtained competitive financing for a 3-year project from the Fundación La Marató de TV3 (€ 149,875) in coordination with a research team from IDIBAPS (Barcelona); where she acted as general coordinator of the application (total granted € 298,963). In addition, it also obtained support from the Spanish Society of Cardiology (SEC) in the call "Basic research projects in cardiology" (€ 20,000).
The main line of research of the group is the study of the molecular mechanisms involved in cardiac hypertrophy and the identification of new therapeutic targets for its treatment. In recent years they have focused on the identification of new cardiokines, proteins secreted by the heart with autocrine, paracrine and / or endocrine properties that may be important both for the treatment of heart disease and for their possible use as biomarkers for diagnosis. of heart disease. This line, developed entirely under his initiative and role, has provided results of extraordinary importance and maximum international relevance, as the published works demonstrate. He has also developed fruitful collaborations with national cardiology groups: Dr. G. Garrabou / Dr. J. Fernández-Solà, Hospital Clínic (Barcelona), Dr. A. Bayes-Genis, Hospital Germans Trias i Pujol (Badalona) and Dr. M Sitges, Hospital Clínico (Barcelona) and international groups: Dr. M. Vinciguerra, London and Dr. Marc van Bilsen, The Netherlands.
In recent years he has participated in several national and international conferences with selected oral communications. Since 2017 she is the coordinator of the "Basic and Translational Research Working Group" of the Catalan Society of Cardiology (SCC).
- Ruperez CH, Ferrer G, Cervera-Barea A, Florit L, Guitart-Mampel M, Garrabou G, MATIAS ZAMORA RODRÍGUEZ, Fàtima Crispi Brillas, Fernandez-Solà J, Lupón J, Bayes-Genis A, Villarroya F and Planavila A Meteorin-like/Meteorin-ß protects heart against cardiac dysfunction. JOURNAL OF EXPERIMENTAL MEDICINE . 218(5): .
- Ferrer G, Guitart-Mampel M, Ruperez CH, MATIAS ZAMORA RODRÍGUEZ, Fàtima Crispi Brillas, Villarroya F, Fernández-Solà J, Garrabou G and Planavila A The protective effect of fibroblast growth factor-21 in alcoholic cardiomyopathy: a role in protecting cardiac mitochondrial function. J PATHOL . 253(2): 198-208.
- Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya F and Vazquez M SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1a-LIPIN 1 pathway and increasing CD36 through Nrf2. CELL COMMUN SIGNAL . 18(1): 147-147.